BehaVR Partners to Advance Virtual Reality for Social Anxiety Disorder
Summary
The company has entered into a new joint development and collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. to create a general wellness product that uses virtual reality (VR) to assist in the management of SAD. “Decades of research have shown that VR is a powerful way to augment traditional cognitive behavioral therapies — including exposure, arousal reduction, active coping, and emotion regulation — which are often used to treat SAD,” said Dr. Peter Buecker, Chief Medical Officer of BehaVR. “Virtual reality has the potential to make good care and management for social anxiety disorder more accessible to people around the world,” said Aaron Gani, founder and CEO of BehaVR. BehaVR is advancing healthcare access and delivery and improving patient outcomes and experiences through the pioneering use of virtual reality (VR), cloud computing, and machine learning. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.